Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Tianjin Huanhu Hospital
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06939166CT.gov Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autoimmune Encephalitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ucar T-Cell (this asset) | Tianjin Huanhu Hospital | Early P1 | C · 39 |
| Cyclophosphamide | Tongji Hospital | P2 | BB |
| Immunoglobulin G2, Anti-(Human Cd19 (Antigen)) (Synthetic Human Monoclonal Medi-551 Heavy Chain), Disulfide With Synthetic Human Monoclonal Medi-551 .Kappa.-Chain, Dimer | University of Utah | P2 | CCC |
| Rituximab | University of Cambridge | P2 | CCC |
| Human Immunoglobulins | University of Utah | P2 | CCC |
| Fludarabine | Tongji Hospital | P1 | CCC |
| Universal Cd19 Car-Γδt Cell | Tongji Hospital | P1 | CC |
| Bcma Targeted Car T-Cells | Tongji Hospital | Early P1 | C |
| ct103a cells | Tongji Hospital | Early P1 | C |
+1 more in the Autoimmune Encephalitis cohort
Other indications for Ucar T-Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| IgA Glomerulonephritis | — | P1 | CCC · 50 |
| Systemic Lupus Erythematosus | — | P1 | CCC · 50 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | — | P1 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideTongji HospitalBB
- Immunoglobulin G2, Anti-(Human Cd19 (Antigen)) (Synthetic Human Monoclonal Medi-551 Heavy Chain), Disulfide With Synthetic Human Monoclonal Medi-551 .Kappa.-Chain, DimerUniversity of UtahCCC
- RituximabUniversity of CambridgeCCC
- Human ImmunoglobulinsUniversity of UtahCCC
- FludarabineTongji HospitalCCC
Citation
Floatz Terminal. Ucar T-Cell in Autoimmune Encephalitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ucar-t-cell-autoimmune-encephalitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →